Regeneron Pharmaceuticals Inc. and bluebird bio Inc. are teaming up in a cell therapy collaboration, and they hope together to overcome some of the safety and efficacy challenges that have faced the first generation of chimeric antigen receptor T-cell (CAR-T) therapies.
The two companies announced a deal Aug. 6 to collaborate on the discovery and development of antibodies and T-cell receptors directed against tumor-specific proteins and peptides. Under the arrangement, Regeneron has agreed to make a $100m equity investment in bluebird, at a substantial 59% premium to the $150 closing price on Aug. 3
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?